{
    "xml": "<topic id=\"PHP3080\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/ropinirole\" basename=\"ropinirole\" title=\"ROPINIROLE\">\n<title>ROPINIROLE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_686\" namespace=\"/interactions/list-of-drug-interactions/dopaminergics/ropinirole\">Ropinirole</xref>\n</p>\n<data name=\"vtmid\">108473005</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_157437168\" title=\"Dopamine receptor agonists\">Dopamine receptor agonists</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP53333\" outputclass=\"indicationsAndDose\" rev=\"1.36\" parent=\"/drugs/ropinirole\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Parkinson's disease, either used alone or as adjunct to co-beneldopa or co-careldopa</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using immediate-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 750&#8239;micrograms daily in 3 divided doses, then increased in steps of 750&#8239;micrograms daily, dose to be increased at weekly intervals, increased to 3&#8239;mg daily in 3 divided doses, then increased in steps of 1.5&#8211;3&#8239;mg daily, adjusted according to response, dose to be increased at weekly intervals; usual dose 9&#8211;16&#8239;mg daily in 3 divided doses, higher doses may be required if used with levodopa, when administered as adjunct to levodopa, concurrent dose of levodopa may be reduced by approx. 20%, daily maximum dose to be given in 3 divided doses; maximum 24&#8239;mg per day.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By mouth using modified-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 2&#8239;mg once daily for 1 week, then 4&#8239;mg once daily, increased in steps of 2&#8239;mg at least every 1&#8239;week, adjusted according to response, increased to up to 8&#8239;mg once daily, dose to be increased further if still no response; increased in steps of 2&#8211;4&#8239;mg at least every 2&#8239;weeks if required; maximum 24&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Parkinson&#8217;s disease in patients transferring from ropinirole immediate-release tablets</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using modified-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially ropinirole modified-release once daily substituted for total daily dose equivalent of ropinirole immediate-release tablets; if control not maintained after switching, titrate dose, consider slower titration in patients over 75 years, when administered as adjunct to levodopa, concurrent dose of levodopa may gradually be reduced by approx. 30%, if treatment interrupted for 1 day or more, consider re-initiation with immediate-release tablets.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Moderate to severe restless legs syndrome</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using immediate-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 250&#8239;micrograms once daily for 2 days, increased if tolerated to 500&#8239;micrograms once daily for 5 days, then increased if tolerated to 1&#8239;mg once daily for 7 days, then increased in steps of 500&#8239;micrograms daily, adjusted according to response, dose to be increased at weekly intervals; usual dose 2&#8239;mg once daily, doses to be taken at night, repeat dose titration if restarting after interval of more than a few days; maximum 4&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseAdjustments\">\n<title>Dose adjustments due to interactions</title>\n<sectiondiv>\n<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53151\" outputclass=\"unlicensedUse\" rev=\"1.8\" parent=\"/drugs/ropinirole\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>Doses in the BNF may differ from those in product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53393\" outputclass=\"importantSafetyInformation\" rev=\"1.8\" parent=\"/drugs/ropinirole\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Impulse control disorders</p>\n<p>Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53410\" outputclass=\"cautions\" rev=\"1.14\" parent=\"/drugs/ropinirole\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Elderly</ph>; <ph outputclass=\"caution\">major psychotic disorders</ph>; <ph outputclass=\"caution\">severe cardiovascular disease (risk of hypotension&#8212;monitor blood pressure)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53324\" outputclass=\"interactions\" rev=\"1.11\" parent=\"/drugs/ropinirole\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (ropinirole).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53181\" outputclass=\"sideEffects\" rev=\"1.9\" parent=\"/drugs/ropinirole\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">confusion</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">dyskinesia</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">fatigue</ph>; <ph outputclass=\"sideEffect\">gastro-oesophageal reflux disease</ph>; <ph outputclass=\"sideEffect\">hallucinations</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">nervousness</ph>; <ph outputclass=\"sideEffect\">peripheral oedema</ph>; <ph outputclass=\"sideEffect\">sudden onset of sleep</ph>; <ph outputclass=\"sideEffect\">syncope</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Compulsive behaviour</ph>; <ph outputclass=\"sideEffect\">psychosis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hepatic disorders</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Paradoxical worsening of restless legs syndrome</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53312\" outputclass=\"pregnancy\" parent=\"/drugs/ropinirole\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid unless potential benefit outweighs risk&#8212;toxicity in <i>animal </i>studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53432\" outputclass=\"breastFeeding\" parent=\"/drugs/ropinirole\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>May suppress lactation&#8212;avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53363\" outputclass=\"hepaticImpairment\" parent=\"/drugs/ropinirole\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53286\" outputclass=\"renalImpairment\" parent=\"/drugs/ropinirole\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid if eGFR less than 30&#8239;mL/ minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53162\" outputclass=\"treatmentCessation\" rev=\"1.10\" parent=\"/drugs/ropinirole\">\n<title>Treatment cessation</title>\n<body>\n<section>\n<sectiondiv>\n<p>Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53299\" outputclass=\"patientAndCarerAdvice\" rev=\"1.18\" parent=\"/drugs/ropinirole\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"adviceAroundDrivingAndOtherTasks\">\n<title>Driving and skilled tasks</title>\n<sectiondiv>\n<p outputclass=\"title\">Sudden onset of sleep</p>\n<p>Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.</p>\n<p>Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.</p>\n<p>Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Hypotensive reactions</p>\n<p>Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53105\" outputclass=\"nationalFunding\" rev=\"1.9\" parent=\"/drugs/ropinirole\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>\n<i>The Scottish Medicines Consortium</i> has advised (June 2006) that <i>Adartrel</i>\n<tm tmtype=\"reg\"/> should be restricted for use in patients with a baseline score of 24 points or more on the International Restless Legs Scale.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP3080-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/ropinirole\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension, oral solution, powder</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77088\" title=\"Tablet\" namespace=\"/drugs/ropinirole/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77095\" title=\"Modified-release tablet\" namespace=\"/drugs/ropinirole/modified-release-tablet\">Modified-release tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78531\" namespace=\"/treatment-summaries/parkinsons-disease-and-related-disorders\" title=\"Parkinson&#8217;s disease and related disorders\" count=\"1\" rel=\"backlink\">Parkinson&#8217;s disease and related disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78560\" namespace=\"/treatment-summaries/substance-dependence\" title=\"Substance dependence\" count=\"1\" rel=\"backlink\">Substance dependence</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_686\" namespace=\"/interactions/list-of-drug-interactions/dopaminergics/ropinirole\" title=\"Ropinirole\" count=\"1\" rel=\"link\">Ropinirole</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77088\" namespace=\"/drugs/ropinirole/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77095\" namespace=\"/drugs/ropinirole/modified-release-tablet\" title=\"Modified-release tablet\" count=\"1\" rel=\"link\">Modified-release tablet</xref>\n</links>\n</topic>",
    "id": "PHP3080",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/ropinirole",
    "basename": "ropinirole",
    "title": "ROPINIROLE",
    "interactants": [
        {
            "id": "bnf_int_686",
            "label": "Ropinirole"
        }
    ],
    "vtmid": "108473005",
    "drugClassification": [
        "Dopamine receptor agonists"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Parkinson's disease, either used alone or as adjunct to co-beneldopa or co-careldopa",
                        "html": "Parkinson's disease, either used alone or as adjunct to co-beneldopa or co-careldopa"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using modified-release medicines"
                    ],
                    "textContent": "By mouth using modified-release medicines",
                    "html": "By mouth using modified-release medicines"
                },
                "adult": [
                    {
                        "textContent": "Initially 750 micrograms daily in 3 divided doses, then increased in steps of 750 micrograms daily, dose to be increased at weekly intervals, increased to 3 mg daily in 3 divided doses, then increased in steps of 1.5&#8211;3 mg daily, adjusted according to response, dose to be increased at weekly intervals; usual dose 9&#8211;16 mg daily in 3 divided doses, higher doses may be required if used with levodopa, when administered as adjunct to levodopa, concurrent dose of levodopa may be reduced by approx. 20%, daily maximum dose to be given in 3 divided doses; maximum 24 mg per day.",
                        "html": "<p>Initially 750&#8239;micrograms daily in 3 divided doses, then increased in steps of 750&#8239;micrograms daily, dose to be increased at weekly intervals, increased to 3&#8239;mg daily in 3 divided doses, then increased in steps of 1.5&#8211;3&#8239;mg daily, adjusted according to response, dose to be increased at weekly intervals; usual dose 9&#8211;16&#8239;mg daily in 3 divided doses, higher doses may be required if used with levodopa, when administered as adjunct to levodopa, concurrent dose of levodopa may be reduced by approx. 20%, daily maximum dose to be given in 3 divided doses; maximum 24&#8239;mg per day.</p>"
                    },
                    {
                        "textContent": "Initially 2 mg once daily for 1 week, then 4 mg once daily, increased in steps of 2 mg at least every 1 week, adjusted according to response, increased to up to 8 mg once daily, dose to be increased further if still no response; increased in steps of 2&#8211;4 mg at least every 2 weeks if required; maximum 24 mg per day.",
                        "html": "<p>Initially 2&#8239;mg once daily for 1 week, then 4&#8239;mg once daily, increased in steps of 2&#8239;mg at least every 1&#8239;week, adjusted according to response, increased to up to 8&#8239;mg once daily, dose to be increased further if still no response; increased in steps of 2&#8211;4&#8239;mg at least every 2&#8239;weeks if required; maximum 24&#8239;mg per day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Parkinson&#8217;s disease in patients transferring from ropinirole immediate-release tablets",
                        "html": "Parkinson&#8217;s disease in patients transferring from ropinirole immediate-release tablets"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using modified-release medicines"
                    ],
                    "textContent": "By mouth using modified-release medicines",
                    "html": "By mouth using modified-release medicines"
                },
                "adult": [
                    {
                        "textContent": "Initially ropinirole modified-release once daily substituted for total daily dose equivalent of ropinirole immediate-release tablets; if control not maintained after switching, titrate dose, consider slower titration in patients over 75 years, when administered as adjunct to levodopa, concurrent dose of levodopa may gradually be reduced by approx. 30%, if treatment interrupted for 1 day or more, consider re-initiation with immediate-release tablets.",
                        "html": "<p>Initially ropinirole modified-release once daily substituted for total daily dose equivalent of ropinirole immediate-release tablets; if control not maintained after switching, titrate dose, consider slower titration in patients over 75 years, when administered as adjunct to levodopa, concurrent dose of levodopa may gradually be reduced by approx. 30%, if treatment interrupted for 1 day or more, consider re-initiation with immediate-release tablets.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Moderate to severe restless legs syndrome",
                        "html": "Moderate to severe restless legs syndrome"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using immediate-release medicines"
                    ],
                    "textContent": "By mouth using immediate-release medicines",
                    "html": "By mouth using immediate-release medicines"
                },
                "adult": [
                    {
                        "textContent": "Initially 250 micrograms once daily for 2 days, increased if tolerated to 500 micrograms once daily for 5 days, then increased if tolerated to 1 mg once daily for 7 days, then increased in steps of 500 micrograms daily, adjusted according to response, dose to be increased at weekly intervals; usual dose 2 mg once daily, doses to be taken at night, repeat dose titration if restarting after interval of more than a few days; maximum 4 mg per day.",
                        "html": "<p>Initially 250&#8239;micrograms once daily for 2 days, increased if tolerated to 500&#8239;micrograms once daily for 5 days, then increased if tolerated to 1&#8239;mg once daily for 7 days, then increased in steps of 500&#8239;micrograms daily, adjusted according to response, dose to be increased at weekly intervals; usual dose 2&#8239;mg once daily, doses to be taken at night, repeat dose titration if restarting after interval of more than a few days; maximum 4&#8239;mg per day.</p>"
                    }
                ]
            }
        ],
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "title": "Dose adjustments due to interactions",
                "textContent": "Dose adjustment may be necessary if smoking started or stopped during treatment.",
                "html": "<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>"
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "Doses in the BNF may differ from those in product literature.",
                "html": "<p>Doses in the BNF may differ from those in product literature.</p>"
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Impulse control disorders",
                "textContent": "Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.",
                "html": "<p>Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.</p>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Elderly",
                "html": "Elderly"
            },
            {
                "type": "cautions",
                "textContent": "major psychotic disorders",
                "html": "major psychotic disorders"
            },
            {
                "type": "cautions",
                "textContent": "severe cardiovascular disease (risk of hypotension&#8212;monitor blood pressure)",
                "html": "severe cardiovascular disease (risk of hypotension&#8212;monitor blood pressure)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (ropinirole).",
                "html": "<p>Appendix 1 (ropinirole).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "confusion",
                        "html": "confusion",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyskinesia",
                        "html": "dyskinesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "fatigue",
                        "html": "fatigue",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastro-oesophageal reflux disease",
                        "html": "gastro-oesophageal reflux disease",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hallucinations",
                        "html": "hallucinations",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nervousness",
                        "html": "nervousness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "peripheral oedema",
                        "html": "peripheral oedema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sudden onset of sleep",
                        "html": "sudden onset of sleep",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "syncope",
                        "html": "syncope",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Compulsive behaviour",
                        "html": "Compulsive behaviour",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "psychosis",
                        "html": "psychosis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Hepatic disorders",
                        "html": "Hepatic disorders",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Paradoxical worsening of restless legs syndrome",
                        "html": "Paradoxical worsening of restless legs syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid unless potential benefit outweighs risk&#8212;toxicity in animal studies.",
                "html": "<p>Avoid unless potential benefit outweighs risk&#8212;toxicity in <i>animal </i>studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "May suppress lactation&#8212;avoid.",
                "html": "<p>May suppress lactation&#8212;avoid.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;no information available.",
                "html": "<p>Avoid&#8212;no information available.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid if eGFR less than 30 mL/ minute/1.73 m2.",
                "html": "<p>Avoid if eGFR less than 30&#8239;mL/ minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ]
    },
    "treatmentCessation": {
        "treatmentCessation": [
            {
                "type": "treatmentCessation",
                "textContent": "Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.",
                "html": "<p>Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "adviceAroundDrivingAndOtherTasks": [
            {
                "type": "adviceAroundDrivingAndOtherTasks",
                "title": "Sudden onset of sleep",
                "textContent": "Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.\n\nPatients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.\n\nManagement of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.",
                "html": "<p>Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.</p><p>Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.</p><p>Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.</p>"
            },
            {
                "type": "adviceAroundDrivingAndOtherTasks",
                "title": "Hypotensive reactions",
                "textContent": "Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.",
                "html": "<p>Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.</p>"
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised (June 2006) that Adartrel should be restricted for use in patients with a baseline score of 24 points or more on the International Restless Legs Scale.",
                "html": "<p> <i>The Scottish Medicines Consortium</i> has advised (June 2006) that <i>Adartrel</i> <tm tmtype=\"reg\"/> should be restricted for use in patients with a baseline score of 24 points or more on the International Restless Legs Scale.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension",
                "oral solution",
                "powder"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77088",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77095",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78531",
                "label": "Parkinson&#8217;s disease and related disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78560",
                "label": "Substance dependence",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_686",
                "label": "Ropinirole",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77088",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77095",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            }
        ]
    }
}